Overview

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC

Status:
Not yet recruiting

Trial end date:
2033-09-01

Target enrollment:

Participant gender:

Summary

Circulating tumor DNA (ctDNA) has been demonstrated to be an effective prognostic marker in breast cancer. Various studies have shown that early TNBC breast cancer patients with positive ctDNA have high risk of cancer recurrence and worse prognosis. This study aimed to identify TNBC patients with positive ctDNA and initiate boost therapy in these high risk patients.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Apatinib
Capecitabine